ProShare Advisors LLC Grows Stock Holdings in Chemed Corporation $CHE

ProShare Advisors LLC boosted its stake in shares of Chemed Corporation (NYSE:CHE) by 1.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,504 shares of the company’s stock after buying an additional 779 shares during the quarter. ProShare Advisors LLC owned 0.39% of Chemed worth $27,513,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its stake in shares of Chemed by 69.3% during the 2nd quarter. Acadian Asset Management LLC now owns 250,722 shares of the company’s stock worth $122,056,000 after acquiring an additional 102,597 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Chemed during the second quarter worth $2,992,000. Parkside Financial Bank & Trust boosted its position in Chemed by 86.3% during the second quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock worth $46,000 after purchasing an additional 44 shares in the last quarter. AGF Management Ltd. purchased a new stake in Chemed during the second quarter worth $2,432,000. Finally, Savant Capital LLC acquired a new stake in Chemed in the second quarter valued at $378,000. 95.85% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Patrick P. Grace sold 150 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares in the company, valued at approximately $1,574,135.83. This represents a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the sale, the chief executive officer directly owned 96,197 shares in the company, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.29% of the company’s stock.

Chemed Trading Up 2.2%

Shares of CHE stock opened at $445.60 on Wednesday. The company has a market capitalization of $6.31 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 2.69 and a beta of 0.43. The firm has a 50-day moving average price of $445.11 and a 200 day moving average price of $485.61. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.39 by ($0.12). The firm had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.Chemed’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the business earned $5.64 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, research analysts predict that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Monday, November 17th will be issued a $0.60 dividend. The ex-dividend date is Monday, November 17th. This represents a $2.40 annualized dividend and a yield of 0.5%. Chemed’s payout ratio is 12.69%.

Analyst Upgrades and Downgrades

CHE has been the subject of several research reports. Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and lifted their price target for the stock from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Bank of America reduced their price target on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Royal Bank Of Canada lowered their price target on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Chemed currently has a consensus rating of “Moderate Buy” and an average price target of $574.25.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.